How do you know if your episodic migraine patient with 5 migraine days/month is a candidate for an anti-CGRP treatment?
The American Headache Society issued a statement regarding the criteria for the initiation of anti-CGRP mAbs for migraine prevention:
Patient is ≥18 years old and medication is prescribed by a licensed medical professional
- 4-7 headache days per month: Patients (with or without aura) should consider anti-CGRP treatment option if they 1) have failed at least 2 prior preventatives and 2) suffer from at least moderate disability (MIDAS > 11, HIT-6 > 50).
- 8-14 headache days per month: Patients (with or without aura) should consider an anti-CGRP treatment option if they have failed at least 2 other preventatives.
Knowing the AHS guidelines, how would you determine if a patient with episodic migraine with 5 migraine days/month is a candidate for anti-CGRP mAbs treatment as a preventive option?
CGRP = calcitonin gene-related peptide
mAbs = monoclonal antibodies
MIDAS = Migraine Disability Assessment
HIT-6 = six-item Headache Impact Test
Reference: American Headache Society. Headache. 2018; 59:1-18.
USA-334-82766
